Start the conversation
In a brand new research report, Zacks Equity Research gave kudos to Wedbush Securities analysts Gregory R. Wade, David M. Nierengarten and Christopher N. Marai for their early "Buy" alert on blood-cancer biotech Pharmacyclics Inc. (Nasdaq: PCYC).
The trio of PhD analysts has been covering the Sunnyvale-based Pharmacyclics for more than a year, Zacks noted. In March, when the stock was trading at $86, they raised their 12-month price target from $110 to $165.
This is premium content for Private Briefing subscribers only.